CN102861052B - Application of Houttuynoid A in medicine for treating ileocecum cancer - Google Patents
Application of Houttuynoid A in medicine for treating ileocecum cancer Download PDFInfo
- Publication number
- CN102861052B CN102861052B CN201210418080.3A CN201210418080A CN102861052B CN 102861052 B CN102861052 B CN 102861052B CN 201210418080 A CN201210418080 A CN 201210418080A CN 102861052 B CN102861052 B CN 102861052B
- Authority
- CN
- China
- Prior art keywords
- houttuynoid
- medicine
- application
- ileocecum cancer
- ileocecum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention discloses application of Houttuynoid A in preparing a medicine for treating ileocecum cancer, which belongs to the technical field of new application of the medicine. According to the assessment on the antineoplastic activity through in-vitro MTTmethod, Houttuynoid A has an obvious inhibiting effect on the growth of human ileocecum cancer cell strain HCT-8. Therefore, Houttuynoid A can be used for preparing the medicine for preventing ileocecum cancer, and has a favorable development and application prospect. The application of Houttuynoid A in preparing the medicine for treating ileocecum cancer, which is provided by the invention, is disclosed for the first time, and because the skeleton type belongs to brand-new skeleton type, the inhibiting activity of Houttuynoid A to ileocecum cancer cells is extremely strong.
Description
Technical field
The present invention relates to the new purposes of compound H outtuynoid A, relate in particular to the application of Houttuynoid A in the anti-ileocecum cancer drug of preparation.
Technical background
Cancer is to one of disease of human life's health hazard maximum, has a large amount of people to die from cancer every year.The research and development of cancer therapy drug are the focuses of study of pharmacy always.In antitumor drug, have 74% to be natural product or derivatives thereof, if paclitaxel and derivant thereof are exactly the reasonable antitumor drug of effect clinically at present.Therefore, from natural product, find anticancer compound or lead compound has great importance.
The compound H outtuynoid A the present invention relates to is one and within 2012, delivers (Chen, S. D. et al., 2012. Houttuynoid A_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.) New skeleton compound, this compound has brand-new framework types, current purposes only relates to anti-herpes simplex virus activity (Chen, S. D. et al., 2012. Houttuynoid A_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.), purposes for the Houttuynoid A the present invention relates in preparation treatment ileocecum cancer drug belongs to open first, because framework types belongs to brand-new framework types, and its inhibition for ileocecum cancerous cell is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other compounds, possesses outstanding substantive distinguishing features, control for ileocecum cancer simultaneously obviously has significant progress.
Summary of the invention
The invention provides the application of compound H outtuynoid A in preparing antitumor drug.
The present invention adopts following technical scheme: the application of Houttuynoid A in the anti-ileocecum cancer drug of preparation, and the structural formula of Houttuynoid A is as shown in formula I:
Formula I
The present invention finds by the evaluation of external MTT anti-tumor activity, and Houttuynoid A also has significant inhibitory action to the growth of human ileocecal carcinoma cell strain HCT-8, suppresses the IC of this 1 strain Growth of Cells
50value is respectively 0.83 ± 0.10 μ M.Therefore, Houttuynoid A can, for the preparation of anti-ileocecum cancer drug, have good development prospect.
The purposes of the Houttuynoid A the present invention relates in preparation treatment ileocecum cancer drug belongs to open first, because framework types belongs to brand-new framework types, and its inhibition for ileocecum cancerous cell is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other compounds, possess outstanding substantive distinguishing features, the control for ileocecum cancer simultaneously obviously has significant progress.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subject to any restriction of specific embodiment, but be limited by claim.
The specific embodiment
The preparation method of compound H outtuynoid A involved in the present invention is referring to document (Chen, S. D. et al., 2012. Houttuynoid A_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subject to any restriction of specific embodiment, but be limited by claim.
Embodiment 1: the preparation of compound H outtuynoid A tablet involved in the present invention:
Get 20 and digest compound Houttuynoid A, add 180 grams of conventional adjuvants preparing tablet, mix, conventional tablet machine is made 1000.
Embodiment 2: the preparation of compound H outtuynoid A capsule involved in the present invention:
Get 20 and digest compound Houttuynoid A, add the conventional adjuvant of preparing capsule as 180 grams of starch, mix, encapsulatedly make 1000.
Below by pharmacodynamic experiment, further illustrate its pharmaceutically active.
Experimental example: adopt the growth inhibited effect of mtt assay assessing compound Houttuynoid A to human ileocecal carcinoma cell strain
1. method: the cell in growth logarithmic (log) phase: human ileocecal carcinoma cell strain HCT-8(buys from Chinese Academy of Sciences's cell bank) with 1.5 * 10
4concentration kind is in 96 orifice plates.After cell culture 24 h are adherent, suck original culture medium.Test is divided into blank group, drug treating group.Blank group is changed 1640 culture medium containing 10% hyclone; It is 100 μ M that drug treating group is changed containing concentration, 50 μ M, 10 μ M, 1 μ M, 0.1 μ M, 0.01 μ M, 0.001 μ M, the culture medium of the Houttuynoid A of 0.0001 μ M and 0.00001 μ M.Cultivate after 48 h, add the MTT of concentration 5mg/mL, continue to be put in CO
2incubator is cultivated 4 h, then along culture fluid top, suck 100 μ L supernatants, add 100 μ L DMSO, 10 min are placed in dark place, utilize microplate reader (Sunrise company product) to measure light absorption value (wavelength 570nm), and calculating cell survival situation according to light absorption value, 6 repeating holes are established in each processing.Cell survival rate (%)=Δ OD
drug treating/ Δ OD
blank* 100.
2. result: Houttuynoid A has significant inhibitory action to the growth of human ileocecal carcinoma cell strain HCT-8.This compound suppresses the IC of human ileocecal carcinoma cell strain HCT-8 growth
50value is respectively: 0.83 ± 0.10 μ M.
By above-described embodiment, shown, Houttuynoid A of the present invention has good inhibitory action to the growth of human ileocecal carcinoma cell strain HCT-8.Prove thus, it is active that Houttuynoid A of the present invention has anti-ileocecum cancer, can be for the preparation of anti-ileocecum cancer drug.
Claims (1)
- The application of 1.Houttuynoid A in preparation treatment ileocecum cancer drug, described compound H outtuynoid A structure as formula Ishown in:formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210418080.3A CN102861052B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid A in medicine for treating ileocecum cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210418080.3A CN102861052B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid A in medicine for treating ileocecum cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102861052A CN102861052A (en) | 2013-01-09 |
| CN102861052B true CN102861052B (en) | 2014-04-16 |
Family
ID=47440370
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210418080.3A Active CN102861052B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid A in medicine for treating ileocecum cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102861052B (en) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100769654B1 (en) * | 2006-02-07 | 2007-10-23 | 인제대학교 산학협력단 | Composition comprising the extract of Houttuynia cordata for treating or prevening cancer disease |
-
2012
- 2012-10-27 CN CN201210418080.3A patent/CN102861052B/en active Active
Non-Patent Citations (4)
| Title |
|---|
| Houttuynia cordata Thunb Extract Inhibits Cell Growth and Induces Apoptosis in Human Primary Colorectal Cancer Cells;KUANG-CHI LAI etal;《ANTICANCER RESEARCH》;20101231;第30卷;第3549-3556页 * |
| Houttuynoids A-E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata;Shao-Dan Chen etal;《ORGANIC LETTERS》;20120313;第14卷(第7期);第1772-1775页 * |
| KUANG-CHI LAI etal.Houttuynia cordata Thunb Extract Inhibits Cell Growth and Induces Apoptosis in Human Primary Colorectal Cancer Cells.《ANTICANCER RESEARCH》.2010,第30卷第3549-3556页. |
| Shao-DanChenetal.HouttuynoidsA-E Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata.《ORGANIC LETTERS》.2012 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102861052A (en) | 2013-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102861099B (en) | Application of Houttuynoid D in preparing medicine for treating endometrial cancer | |
| CN102861052B (en) | Application of Houttuynoid A in medicine for treating ileocecum cancer | |
| CN102861062B (en) | Application of Houttuynoid C in endometrial cancer treatment medicine | |
| CN102861061B (en) | Application of Houttuynoid B in cholangiocarcinoma treatment medicine | |
| CN102861057B (en) | Application of Houttuynoid D in skin cancer treatment medicine | |
| CN102872074B (en) | Application of Houttuynoid C in drugs for treating kidney cancer | |
| CN102872072B (en) | Application of Houttuynoid B to preparing drugs for treating kidney cancer | |
| CN102872085B (en) | Application of Houttuynoid A in medicines for treating breast cancer | |
| CN102861049B (en) | Application of Houttuynoid A in medicine for treating liver cancer | |
| CN102861058B (en) | Application of Houttuynoid D in cholangiocarcinoma treatment medicine | |
| CN102861078B (en) | Application of Houttuynoid D in medicine for treating prostatic cancer | |
| CN102861056B (en) | Application of Houttuynoid A in endometrial cancer treatment medicine | |
| CN102861074B (en) | Application of Houttuynoid B in medicine for treating bladder cancer | |
| CN102872070B (en) | Application of Houttuynoid C to preparing drugs for treating prostate cancer | |
| CN102872149B (en) | Application of Houttuynoid B in medicament for treating cecum cancer | |
| CN102861080B (en) | Application of Houttuynoid C in medicine for treating nasopharynx cancer | |
| CN102861070B (en) | Application of Houttuynoid E in medicine for treating tongue cancer | |
| CN102872095B (en) | Application of Houttuynoid E in medicine for treating ileocecum cancer | |
| CN102861096B (en) | Application of Houttuynoid E in preparing medicine for treating cervical cancer | |
| CN102861077B (en) | Application of Houttuynoid D in medicine for treating cervical cancer | |
| CN102861079B (en) | Application of Houttuynoid B in medicine for treating skin cancer | |
| CN102861084B (en) | Application of Houttuynoid D in medicine for treating ileocecum cancer | |
| CN102885844B (en) | Application of Houttuynoid B in medicine for treating tongue cancer | |
| CN102872142B (en) | Application of Houttuynoid D in drug for treating ovarian cancer | |
| CN102872101B (en) | Application of Houttuynoid C in medicine for treating ileocecum cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: QIDONG TIANFEN ELECTRIC TOOL TECHNOLOGY INNOVATION Free format text: FORMER OWNER: WU JUNHUA Effective date: 20141126 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 210009 NANJING, JIANGSU PROVINCE TO: 226241 NANTONG, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20141126 Address after: Qidong City, Jiangsu province 226241 Nantong lvsigang Tianfen electric tools trade city comprehensive building Patentee after: Qidong Tianfen Electric Tool Technology Innovation Center Address before: 210009 No. 22, Hankou Road, Gulou District, Jiangsu, Nanjing Patentee before: Wu Junhua |